<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563160</url>
  </required_header>
  <id_info>
    <org_study_id>(193-h)in QE/EC/I</org_study_id>
    <secondary_id>HARECCTR0500015</secondary_id>
    <secondary_id>000904</secondary_id>
    <secondary_id>B9E-IH-O333</secondary_id>
    <nct_id>NCT00563160</nct_id>
  </id_info>
  <brief_title>Study of Efficacy of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small-cell Lung Cancer Before Surgery</brief_title>
  <official_title>Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small Cell Lung Cancer Before Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      To study the activity of chemotherapy with Gemzar-carboplatin in the preoperative setting for
      operable stages of non-small-cell lung cancer and to identify novel molecular markers
      correlated with chemosensitivity and prognosis
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <completion_date type="Anticipated">February 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological response rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measurements</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lung Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine, carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven, newly diagnosed primary bronchogenic non-small
             cell lung cancer

          -  Measurable or evaluable tumour on chest X-ray or CT scan.

          -  No multiple ipsilateral or contralateral parenchymal tumours

          -  Stage I(exceptT1N0),II,IIIa disease as shown by PET-CT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Siu Kie Au, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, Queen Elizabeth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Poon, Dr</last_name>
    <phone>(852) 2958 2310</phone>
    <email>pcm0806@netvigator.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Che Mun Poon, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun Key Law, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roger Ngan, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chung Kong Kwan, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheuk Kin Lo, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johnny Chan, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>TK Au Yong, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting Lok Kwan, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stella Cheung, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Yip</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ekg.org.hk/HAREC-CTR/RegistryDisplay2.jsp?HARECID=HARECCTR0500015</url>
    <description>HAREC Clinical Trial Registry</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

